

CITATION REPORT

List of articles citing

Second-line treatment of hepatocellular carcinoma: from theory to practical issues

DOI: 10.21518/2079-701x-2019-19-30-36
Meditsinskiy Sovet, 2019, , 30-36.

Source: <https://exaly.com/paper-pdf/117030415/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Embrolizumab as second line therapy for hepatocellular patient. <i>Meditinskiy Sovet</i> , 2021 , 150-154	0.4	
1	Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. <i>Meditinskiy Sovet</i> , 2022 , 157-162	0.4	